OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Other EventsItem 8.01—Other Events.
On September 24, 2018, OpGen, Inc. issued a press release announcing a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC, a wholly owned subsidiary of Merck's Healthcare Services and Solutions to develop a research program to detect, track and manage antimicrobial-resistant infections at healthcare institutions in New York State. The full text of such press release is filed as Exhibit 99.1 to this report.
Item 9.01 — Financial Statements and Exhibits.
| 99.1 |
Press Release, dated September 24, 2018, issued by OpGen, Inc.
|
OPGEN INC ExhibitEX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1 OpGen Partnering with New York State Department of Health and Merck’s ILÚM Health Solutions to Detect Antimicrobial-Resistant Infections Collaboration with NY Department of Health’s Wadsworth Center to utilize OpGen’s Acuitas AMR Gene Panel u5.47 and Acuitas Lighthouse Software within Statewide digital health and precision medicine platform at healthcare institutions statewide GAITHERSBURG,…To view the full exhibit click here
About OpGen, Inc. (NASDAQ:OPGN)
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.
